We make select early investments at the Seed stage in private biotech ventures as the lead or sole investor and participate in Series-A investments.

Company Formation

We launch and fund de novo companies to advance important innovations, which may otherwise lack the proper resources to progress and thrive.

Beyond financial support, we work with our portfolio companies by providing management support and development expertise through a group of highly experienced advisors and operators. Together with our portfolio companies, we identify critical value inflection milestones and develop a plan to successfully arrive there. By leveraging the Tellus BioVentures team, we help companies operate in an efficient manner, focused on achieving milestones and transforming innovative science into important therapies for patients.



Aegle Therapeutics

A privately-held biotechnology company developing first in class therapies using extracellular vesicles ("EVs"), including exosomes

Dianthus Therapeutics

A newly formed biotechnology company focused on the discovery and development of monoclonal antibody therapeutics that modulate the immune complement system for the treatment of auto-immune diseases

Interius BioTherapeutics

A newly established biotechnology company transforming cell and gene therapies


A newly formed biotechnology company established to develop novel therapeutics for NAFLD/NASH and Type 2 diabetes

Viridian Therapeutics

A development-stage biotechnology company (NASDAQ: VRDN). Viridian’s most advanced program, VRDN-001, is a clinical-stage anti-IGF-1R monoclonal antibody in development for thyroid eye disease

Zenas BioPharma

A newly formed biopharmaceutical company advancing a portfolio of monoclonal antibodies in development for auto-immune diseases